Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Verona Pharma plc (VRNA)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
a week ago | GlobeNewsWire
2 weeks ago | GlobeNewsWire
3 weeks ago | GlobeNewsWire
2 months ago | Pulse2
2 months ago | GlobeNewsWire
3 months ago | GlobeNewsWire
3 months ago | GlobeNewsWire
3 months ago | GlobeNewsWire
3 months ago | GlobeNewsWire
5 months ago | GlobeNewsWire